Nucleobase Transport at the CNS Barriers

核碱基和核苷类似物广泛用于治疗各种病毒感染和中枢神经系统（CNS）中的其它疾病。 许多CNS靶向核碱基/核苷药物表现出有限的脑渗透，这限制了它们的治疗效果。 在血脑屏障（BBB）和血-脑脊液屏障（脉络丛）处的核碱基转运体可以在控制核碱基/核苷类似物的CNS生物利用度中起关键作用。 详细了解核碱基在中枢神经系统屏障转运的机制，将允许开发策略，以提高中枢神经系统靶向核碱基类似物的脑生物利用度，并避免外周靶向核碱基药物的神经系统副作用。 几个核碱基转运系统已被确认在血脑屏障和脉络丛，然而，潜在的核碱基转运蛋白的分子身份和功能特征尚未阐明。 到目前为止，哺乳动物的核碱基转运蛋白还没有被克隆。 建议的研究将集中在BBB和脉络丛的核碱基转运蛋白的分子鉴定和功能表征。 具体目标是：（1）为哺乳动物核碱基转运蛋白的克隆和鉴定开发克隆策略和表达系统。 (2)从血脑屏障中克隆平衡核碱基转运蛋白并对其功能进行表征。 (3)脉络丛Na+依赖性核碱基转运蛋白的克隆和功能特征。 我们将首先开发新的互补克隆策略，在酵母和合适的表达系统克隆和哺乳动物核碱基转运蛋白的特性。 然后，我们将克隆从BBB和脉络丛使用我们的酵母策略构建的cDNA文库的核碱基转运蛋白。 一旦克隆，我们将在异源表达系统中表达这些核碱基转运蛋白，并研究它们与生理核碱基和临床上重要的核碱基类似物相互作用的功能特征。 还将探索这些转运蛋白在CNS屏障中的分布。 这些研究将极大地推进我们对核碱基及其类似物在CNS屏障上的转运机制的理解。

Nucleobase and nucleoside analogs are widely used in the treatment of various viral infections and other diseases in the central nervous system (CNS). Many CNS targeted nucleobase/nucleoside drugs exhibit limited penetration into the brain, which limits their therapeutic effectiveness. Nucleobase transporters at the blood brain barrier (BBB) and the blood- cerebrospinal fluid barrier (choroid plexus) may play a critical role in governing the CNS bioavailability of nucleobase/nucleoside analogs. A detailed understanding of the mechanisms of nucleobase transport at the CNS barriers will allow the development of strategies to enhance the brain bioavailability of CNS targeted nucleobase analogs and to avoid neurological side effects of peripherally targeted nucleobase drugs. Several nucleobase transport systems have been recognized at the BBB and choroid plexus; however, the molecular identity and functional characteristics of the underlying nucleobase transporters have not been elucidated. To date, mammalian nucleobase transporters have not been cloned. The proposed studies will focus on molecular identification and functional characterization of nucleobase transporters in the BBB and choroid plexus. The specific aims are: (1) Develop cloning strategies and expression systems for cloning and characterization of mammalian nucleobase transporters. (2) Clone and functionally characterize the equilibrative nucleobase transporter from the BBB. (3) Clone and functionally characterize the Na+-dependent nucleobase transporter from the choroid plexus. We will first develop novel complementation cloning strategies in yeast and suitable expression systems for cloning and characterization of mammalian nucleobase transporters. We will then clone the nucleobase transporters from cDNA libraries constructed from the BBB and choroid plexus using our yeast strategy. Once cloned, we will express these nucleobase transporters in heterologous expression systems and investigate their functional characteristics in interacting with physiologic nucleobases and clinically important nucleobase analogs. The distribution of these transporters at the CNS barriers will also be explored. These studies will greatly advance our understanding of the transport mechanisms of nucleobases and their analogs at the CNS barriers.